GenScript Biotech and T-MAXIMUM Biotech have formed a strategic collaboration to develop T-MAXIMUM's CAR-T cell therapy using GenScript's CRISPR nucleic acid reagents. GenScript will provide various CRISPR reagents to support the development of the universal CAR-T products from discovery to commercialisation. T-MAXIMUM Biotech hopes to progress multiple products to the… Read More
A new study has shown that blood thinner warfarin could also treat cancer, as it stops tumours from interfering with a self-destruct mechanism that cells initiate when they detect mutations or other abnormalities (ferroptosis). The research by Columbia University researchers was conducted in human cells and… Read More
Listen to this article on the DDW Podcast: Reece Armstrong speaks to Neil Dhawan, the Co-founder and CEO of Totus Medicines about the company’s approach to drug discovery using fundamental technologies in chemistry, biology and artificial intelligence (AI). RA: How is Totus Medicines attempting to target untreatable or undruggable diseases? ND:… Read More
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted Aleta Biotherapeutics a clinical trial authorisation (CTA) to evaluate biologic ALETA-001 in a Phase I/II clinical trial in patients with B-cell malignancies who are relapsed/refractory to CD19 CAR-T cell therapy. The company’s collaboration partner, Cancer Research UK’s Centre for… Read More
Listen to this article on the DDW Podcast: AstraZeneca UK has appointed David Brocklehurst as Head of Oncology in the UK. He spoke with DDW’s Megan Thomas about how AstraZeneca is innovating to displace chemotherapy and research areas of significance. MT: What will you be focusing on in your new role?… Read More
Astex Pharmaceuticals and MSD (Merck & Co) have announced an exclusive worldwide research collaboration to identify small molecule candidates with activity towards a tumour suppressor protein for the treatment of cancer. Under the terms of the agreement, Astex will apply its fragment-based drug discovery platform to develop compounds targeting multiple… Read More
Astellas Pharma will invest $50 million into Poseida Therapeutics to secure the rights to the company’s cancer CAR-T cell therapy for solid tumours, which is currently in Phase I trials. The total $50 million will include $25 million to acquire 8,333,333 shares of common stock of Poseida and a one-time… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. The pace of innovation in cancer drug discovery showed no signs of slowing… Read More
News round-up for 31 July – 4 August by DDW Digital Content Editor Diana Spencer. The pace of innovation in cancer drug discovery showed no signs of slowing this week, with several pretty momentous discoveries boosting research in the sector. These include the creation of a… Read More
New findings suggest PARP inhibitor drugs, used to treat cancer patients who have an altered BRCA1 or BRCA2 gene, may also be effective for patients which have changes in the SF3B1 gene. If further research supports these findings, there is the potential that existing PARP inhibitor… Read More
Renaissance Pharma has announced its first development programme focused on Hu14.18, a humanised anti-GD2 monoclonal antibody (mAb), licensed from St Jude Children’s Research Hospital for the treatment of newly diagnosed high-risk neuroblastoma. Fifty percent of neuroblastoma patients have high-risk (HRNB) disease which has an overall survival… Read More
Listen to this article on the DDW Podcast: Genoscience Pharma’s Philippe Halfon and Eric Raymond share their expertise on targeting the recycling of unsustainable production of palmitoylated cancer-associated proteins. Cancer relies on palmitoylation for progression Palmitoylation is a global post-translational lipid modification, that controls the localisation, stability, and function of several proteins. Read More
Scientists have unveiled the first and largest encyclopaedia of protein alterations in soft tissue sarcomas – opening the door to a new era of understanding and treatment for this group of rare cancers. The pioneering encyclopaedia, or ‘Rosetta Stone’, of sarcoma biology compiles a wealth of… Read More
Investigators at the Icahn School of Medicine at Mount Sinai have designed an RNA-based strategy to activate dendritic cells that eradicated tumours and prevented their recurrence in mouse models of melanoma. The findings, which suggest that the approach has the potential to be effective against tumours… Read More
This World Lung Cancer Day, DDW’s Diana Spencer takes a look at five 2023 discoveries that could transform the treatment of lung cancer in the near future. Allogeneic cell vaccines In July 2023, Lineage Cell Therapeutics and Cancer Research UK announced encouraging primary and secondary endpoint… Read More
Researchers from the University of Liverpool, UK, have created a biomedical compound that has the potential to stop the spread of breast cancer. Scientists from the Chemistry and Biochemistry Departments at the University of Liverpool and Nanjing Medical School in China have discovered a possible way… Read More
